Areas of Uncertainty in SARS-CoV-2 Vaccination for Cancer Patients.
T cell assay
cellular immunity
humoral immunity
neutralizing antibodies
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
11 Dec 2022
11 Dec 2022
Historique:
received:
30
08
2022
revised:
13
11
2022
accepted:
01
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
Early in the COVID-19 pandemic, it was recognized that infection with SARS-CoV-2 is associated with increased morbidity and mortality in patients with cancer; therefore, preventive vaccination in cancer survivors is expected to be particularly impactful. Heterogeneity in how a neoplastic disease diagnosis and treatment interferes with humoral and cellular immunity, however, poses a number of challenges in vaccination strategies. Herein, the available literature on the effectiveness of COVID-19 vaccines among patients with cancer is critically appraised under the lens of anti-neoplastic treatment optimization. The objective of this review is to highlight areas of uncertainty, where more research could inform future SARS-CoV-2 immunization programs and maximize benefits in the high-risk cancer survivor population, and also minimize cancer treatment deviations from standard practices.
Identifiants
pubmed: 36560527
pii: vaccines10122117
doi: 10.3390/vaccines10122117
pmc: PMC9784623
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Lancet Oncol. 2021 Mar;22(3):309-320
pubmed: 33493433
Nat Immunol. 2019 Sep;20(9):1231-1243
pubmed: 31358999
Euro Surveill. 2020 Dec;25(48):
pubmed: 33272355
Radiother Oncol. 2020 Oct;151:314-321
pubmed: 32730830
Gynecol Oncol. 2022 May;165(2):330-338
pubmed: 35221132
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Lancet Digit Health. 2021 Sep;3(9):e577-e586
pubmed: 34305035
J Thorac Cardiovasc Surg. 2022 Aug;164(2):378-385
pubmed: 35459540
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
ACR Open Rheumatol. 2022 Mar;4(3):238-246
pubmed: 34890478
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
JAMA Oncol. 2021 Oct 1;7(10):1507-1513
pubmed: 34236381
Lancet Infect Dis. 2022 Dec;22(12):1716-1727
pubmed: 36075233
Annu Rev Med. 2022 Jan 27;73:55-64
pubmed: 34637324
Am J Emerg Med. 2021 Feb;40:188-192
pubmed: 33036853
Eur J Cancer. 2020 Dec;141:62-81
pubmed: 33129039
Mayo Clin Proc Innov Qual Outcomes. 2022 Apr;6(2):120-125
pubmed: 34926993
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Eur J Cancer. 2020 Nov;139:43-50
pubmed: 32971510
Eur J Cancer. 2020 Jun;132:122-124
pubmed: 32344292
Ann Oncol. 2021 Jun;32(6):787-800
pubmed: 33746047
Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):631-640
pubmed: 32589990
Int J Infect Dis. 2021 Sep;110:229-231
pubmed: 34216738
BMC Cancer. 2021 May 20;21(1):578
pubmed: 34016086
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
Nature. 2022 Mar;603(7902):706-714
pubmed: 35104837
Nat Cancer. 2021 Dec;2(12):1321-1337
pubmed: 35121900
Sci Immunol. 2022 Dec 23;7(78):eabp8328
pubmed: 35549298
Exp Mol Med. 2021 May;53(5):750-760
pubmed: 33953323
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
PLoS One. 2020 Jun 23;15(6):e0234765
pubmed: 32574165
JAMA Oncol. 2021 Dec 1;7(12):1882-1890
pubmed: 34473192
Pediatr Transplant. 2018 Aug;22(5):e13220
pubmed: 29777573
Nat Med. 2021 Nov;27(11):1990-2001
pubmed: 34522051
N Engl J Med. 2021 Sep 23;385(13):1172-1183
pubmed: 34192426
Lancet Microbe. 2022 May;3(5):e348-e356
pubmed: 35345417
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
J Med Virol. 2015 Feb;87(2):350-6
pubmed: 25080078
JAMA Netw Open. 2021 May 3;4(5):e2111417
pubmed: 34037731
J Clin Virol. 2022 Mar;148:105098
pubmed: 35134681
Front Cell Infect Microbiol. 2020 Nov 25;10:587269
pubmed: 33324574
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
JAMA Oncol. 2022 May 1;8(5):748-754
pubmed: 35266953
J Clin Oncol. 2019 Oct 20;37(30):2795-2804
pubmed: 31465264
In Vivo. 2021 Mar-Apr;35(2):1307-1311
pubmed: 33622935
Am J Obstet Gynecol. 2022 Jun 30;:
pubmed: 35779589
Nature. 2022 Mar;603(7901):493-496
pubmed: 35102312
J Clin Microbiol. 2022 Mar 16;60(3):e0219921
pubmed: 35020419
Int J Surg. 2020 Dec;84:57-65
pubmed: 33122153
Cancer Cell. 2021 Aug 9;39(8):1034-1036
pubmed: 34348121
Br J Anaesth. 2021 Aug;127(2):205-214
pubmed: 34148733
Leukemia. 2021 Sep;35(9):2703-2705
pubmed: 33986431
Lancet. 2022 Apr 2;399(10332):1303-1312
pubmed: 35305296
Mult Scler Relat Disord. 2022 Jan;57:103382
pubmed: 35158475
Blood Cancer Discov. 2022 Mar 01;3(2):95-102
pubmed: 35015688
Cancer Cell. 2020 Aug 10;38(2):161-163
pubmed: 32710820
Clin Microbiol Rev. 2014 Jan;27(1):3-20
pubmed: 24396134
Cancer Res. 2021 Dec 15;81(24):6273-6280
pubmed: 34759001
Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20
pubmed: 34611326
Front Oncol. 2021 Nov 19;11:754838
pubmed: 34868962
Nat Immunol. 2010 Jun;11(6):535-42
pubmed: 20453843
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695
Blood. 2020 Dec 17;136(25):2881-2892
pubmed: 33113551
HPB (Oxford). 2022 Oct;24(10):1668-1678
pubmed: 35562256
Am J Med Sci. 2021 Feb;361(2):216-225
pubmed: 33349441
Cancer Cell. 2021 Aug 9;39(8):1028-1030
pubmed: 34242572
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
JAMA Oncol. 2022 Jan 1;8(1):106-113
pubmed: 34591965
Cell. 2022 May 26;185(11):1875-1887.e8
pubmed: 35523182